Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
Approval of a cystic fibrosis triplet from Vertex looks odds-on – and with the competition lagging behind, the company has free rein on price.
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
The big pharma’s cystic fibrosis deal with Galapagos is greeted with surprise, but the gamble might actually make sense.
Galapagos needs to impress with its cystic fibrosis triplet to have a hope of catching Vertex, while Abbott needs the Coapt study of MitraClip to reach a different…
Filgotinib delivers an important win in its first pivotal rheumatoid arthritis study, setting partners Gilead and Galapagos hot on the heels of Abbvie.
Galapagos and Bayer/Orion will both report phase III data this quarter – the former with filgotinib in arthritis and the latter with darolutamide in prostate cancer.
Celgene's CAR-T and Glaxosmithkline's antibody-drug conjugate are among the industry's most valuable R&D assets.
Trade war and pricing worries weigh heavily on the sector's giants.